The gas-sensing capsule assesses the functional health of a patient’s entire gastrointestinal system and aims to provide: better diagnosis, more targeted and personalized treatment, earlier relief of symptoms and improved healthcare outcomes.
The capsule can electronically report important data by continuously detecting gases and wirelessly transmitting the data to provide insights into the location of the capsule, microbiome function and gastrointestinal health.
The ingestible capsule offers a potential diagnostic tool for many disorders of the gut from motility disorders, IBS and IBD to liver disease.
The Atmo Gas Capsule is currently an investigational device exclusively for use in clinical investigations, and is not available for sale.
Gut disorders are one of the most common ailments in the world affecting tens of millions of people.
These disorders include motility abnormalities, SIBO, IBS and IBD. Gases are important biomarkers of disease, dysfunction and dysbiosis.
The vitamin-sized electronic “Lab-in-a-Pill” measures gaseous biomarkers at the source of production as it passes through the gastrointestinal system. This data is continuously transmitted to a pocket-sized receiver, and sent to the cloud for aggregation, analysis, and diagnosis.
The gas sensors are sealed within a special membrane that allows gas in but keeps out stomach acid and digestive juices.
The capsule aims to determine transit times derived from measures of temperature, relative humidity, hydrogen concentration, and carbon dioxide concentration, in conjunction with indicators of multi-gas, capsule tumble, and antenna reflectance.
October 3, 2023. Atmo Biosciences has reached 60 per cent of its recruitment target for a pivotal clinical study to assess the use of the Atmo Gas Capsule to measure gastrointestinal transit time in p...
September 25, 2023. Breakthrough Victoria today announced it has invested in Atmo Biosciences to support the commercialization of the company’s world-first ingestible gas-sensing capsule that can he...
August 25, 2023. Atmo Biosciences is one of only five businesses accepted into the market-leading ANDHealth+ commercialization program, which helps digital health companies to scale their products nat...
August 10, 2023. Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, today announced it has c...
6 July, 2023. A Monash University clinical study published in the journal Alimentary Pharmacology & Therapeutics1 has found that Atmo Biosciences’ gas-sensing capsule can be used to provide insi...
17 May, 2023. Preliminary results from a University of Queensland (UQ) study to assess how the Atmo Gas Capsule compares to established SIBO (small intestinal bacterial overgrowth) diagnostic methods ...
AUSBIZ
The tiny device revolutionising gut health diagnostics
24 September 2021
AUSTRALIAN FINANCIAL REVIEW
Gut health medtech Atmo Biosciences raises $9.6m
23 September 2021
BBC
Gas detecting pill could diagnose poor gut health
23 January 2018
Kalantar-Zadeh, K., Berean, K.J., Burgell, R.E. et al. Intestinal gases: influence on gut disorders and the role of dietary manipulations. Nat Rev Gastroenterol Hepatol 16, 733–747 (2019). https://doi.org/10.1038/s41575-019-0193-z